Sulfamethoxazole
Pneumocystosis
Texas Tech University Health Sciences CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pneumocystosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trimethoprim Texas Tech University Health Sciences Center | Phase 4 | BB |
Same molecule, other indications
Sulfamethoxazole is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BBB
Indicative · Phase 4
75 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →